TOKYO, Mar 18 (Pulse News Wire) – Nano Holdings,inc. (4571.T) announced changes to its board of directors effective April 1, shifting its primary business focus to investments.
CEO Jun Matsumura will continue his role, while Akio Akihara transitions from non-executive CTO to executive CTO with responsibility for scientific evaluation of target companies and leadership of NANO MRNA Co., Ltd. Additionally, Takashi Matsuo will take on CFO duties alongside his existing roles as CAO and CCO to strengthen financial functions for the shift towards investment operations. The company will now operate as an investment holding firm, focusing on growth strategies in healthcare and biotech sectors both domestically and internationally through subsidiaries such as Nano Bridge Investment Co., Ltd. and Nano Holdings US, LLC.
Key personnel changes include: - Jun Matsumura: Retains position as President and CEO, also serving as a director at NBI. - Nobuhiro Tokushige: Assumes role as CGO. - Takashi Matsuo: Takes on additional CFO responsibilities. - Akio Akihara: Promoted to CTO with oversight of NANO MRNA Co., Ltd.
These moves aim to clarify accountability within the investment sector and maximize returns through strategic partnerships and enhanced management structures.
🟢 Confidence: High AI-translated content.